Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Tiny Alpha-Seeds target returned prostate cancer in first human test

NCT ID NCT06202248

First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 21 times

Summary

This study tests whether a new type of radiation seed, called DaRT, can safely treat prostate cancer that has returned after initial treatment. Ten men with non-metastatic, locally recurrent prostate cancer will receive the seeds directly into the tumor. The main goal is to see if the seeds can be placed correctly and safely, with a secondary focus on quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY RECURRENT PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • RAMBAM Health Care Campus

    RECRUITING

    Haifa, 3109601, Israel

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.